Lijun Liu

Xishiku Street No.8
Beijing, 100034, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 84 publications

Telitacicept for IgA Nephropathy - Interim Analysis of a Phase 3 Trial.

Telitacicept for IgA Nephropathy - Interim Analysis of a Phase 3 Trial.

Journal: The New England journal of medicine

Published: May 13, 2026

Case report: Sequential complement inhibition and BAFF/APRIL blockade in progressive IgA nephropathy and IgA vasculitis nephritis: a report of two cases.

Case report: Sequential complement inhibition and BAFF/APRIL blockade in progressive IgA nephropathy and IgA vasculitis nephritis: a report of two cases.

Journal: Frontiers in immunology

Published: April 27, 2026

The heterogeneity of dopamine-mediated vasodilation in human intrarenal arteries.

The heterogeneity of dopamine-mediated vasodilation in human intrarenal arteries.

Journal: Journal of advanced research

Published: March 31, 2026

Glucocorticoid-Modulated Molecular Signatures and Prediction of Treatment Efficacy in IgA Nephropathy.

Glucocorticoid-Modulated Molecular Signatures and Prediction of Treatment Efficacy in IgA Nephropathy.

Journal: Journal of the American Society of Nephrology : JASN

Published: March 21, 2026

Circulating Antinephrin Antibodies in Adult Chinese Patients With IgAN and Nephrotic-Range Proteinuria.

Circulating Antinephrin Antibodies in Adult Chinese Patients With IgAN and Nephrotic-Range Proteinuria.

Journal: Kidney international reports

Published: December 03, 2025

Association Between Relapse and Long-Term Kidney Outcomes in IgA Nephropathy.

Association Between Relapse and Long-Term Kidney Outcomes in IgA Nephropathy.

Journal: Kidney medicine

Published: November 10, 2025

Complement factor H supplementation rather than complete C3 knockout provides therapeutic benefits in IgA nephropathy.

Complement factor H supplementation rather than complete C3 knockout provides therapeutic benefits in IgA nephropathy.

Journal: Molecular biomedicine

Published: October 29, 2025

Endothelin Receptor Antagonist Ambrisentan, Sodium-Glucose Cotransporter 2 Inhibitor Henagliflozin, and Their Combination in IgA Nephropathy: A Randomized Crossover Trial.

Endothelin Receptor Antagonist Ambrisentan, Sodium-Glucose Cotransporter 2 Inhibitor Henagliflozin, and Their Combination in IgA Nephropathy: A Randomized Crossover Trial.

Journal: Journal of the American Society of Nephrology : JASN

Published: October 10, 2025

Efficacy of once-weekly teriparatide versus alendronate in Chinese postmenopausal osteoporosis: a randomised, open-label, active-controlled, 48-week, multicentre phase III study.

Efficacy of once-weekly teriparatide versus alendronate in Chinese postmenopausal osteoporosis: a randomised, open-label, active-controlled, 48-week, multicentre phase III study.

Journal: Journal of orthopaedic translation

Published: August 14, 2025

C5 inhibitor attenuates cholesterol crystal embolism-induced thrombotic microangiopathy and acute kidney injury.

C5 inhibitor attenuates cholesterol crystal embolism-induced thrombotic microangiopathy and acute kidney injury.

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Published: August 10, 2025

The Proportion of New-Onset Microangiopathic Lesions in IgA Nephropathy is Increased After COVID-19 Pandemic in China.

The Proportion of New-Onset Microangiopathic Lesions in IgA Nephropathy is Increased After COVID-19 Pandemic in China.

Journal: Kidney medicine

Published: August 01, 2025

Effects of Podocyte Foot Process Effacement on Kidney Prognosis and Response to Immunosuppressive Therapy in IgA Nephropathy.

Effects of Podocyte Foot Process Effacement on Kidney Prognosis and Response to Immunosuppressive Therapy in IgA Nephropathy.

Journal: Kidney medicine

Published: July 31, 2025

Showing 1-12 of 84

Last Updated: 09/26/2026